Short-bowel syndrome

7 trials 2 recruiting MedDRA PT
7 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
Mechanism of action (INN-stem analysis)
GLP-1 receptor agonist 2 substances
Unknown / small molecule 1 substance
Phase III: 5 Phase II: 1 Other: 2

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

5 trials
  • VectivBio AG Commercial
    APRAGLUTIDE
    2023-510389-28-00 11 countries 2021 n=101 Orphan
    Ended
  • Zealand Pharma A/S Commercial
    GLEPAGLUTIDE
    2024-512486-14-00 14 countries 2026 n=72
    Recruiting
  • Zealand Pharma A/S Commercial
    GLEPAGLUTIDE
    2024-513373-43-00 6 countries 2021 n=49
    Ended
  • Zealand Pharma A/S Commercial
    GLEPAGLUTIDE
    2024-513374-22-00 5 countries 2019 n=77
    Ended
  • Zealand Pharma A/S Commercial
    GLEPAGLUTIDE
    2025-520775-81-00 4 countries 2025 n=19
    Ended

Phase II

1 trial
  • Hanmi Pharm. Co. Ltd. Commercial
    HUMAN GLUCAGON-LIKE PEPTIDE-2 ANALOGUE LINKED TO A HUMAN IMMUNOGLOBULIN FC FRAGMENT
    2024-515160-32-00 5 countries 2022 n=13 Orphan
    Recruiting

Other

2 trials
  • VectivBio AG Commercial
    IMP not specified
    2023-504430-22-00 1 country 2023 n=33
    Ended
  • VectivBio AG Academic
    IMP not specified
    2023-504430-22-00 1 country 2023 n=33
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Zealand Pharma A/S Commercial 4 Phase III 1
VectivBio AG Commercial 3 Other, Phase III 0
Hanmi Pharm. Co. Ltd. Commercial 1 Phase II 1
New trials by year
2019
1
2021
2
2022
1
2023
2
2025
1
2026
1
← All indication landscapes